Payment overview · 2025
General Payments
$2,440.33
115 reported records · 18 companies
Healthcare provider profile · identity verified
Ashok A Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BRIDGEWATER, NJ · NPI 1497728745
Verified facts
What the public records show
CMS Open Payments records show Ashok A Patel, MD received $2,440.33 in general payments during 2025 across 115 reported records.
Medtronic, Inc. accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$865.84 | 35.5% | 40 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $790.79 | 32.4% | 38 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $108.59 | 4.5% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.80 | 3.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.52 | 2.9% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $57.85 | 2.4% | 3 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $54.64 | 2.2% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $49.67 | 2.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $48.85 | 2.0% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $47.26 | 1.9% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $46.51 | 1.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.18 | 1.8% | 3 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $42.72 | 1.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $37.44 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.40 | 1.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.79 | 1.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $22.84 | 0.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.64 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,440.33 | 115 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $592.41 | 31 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $232.86 | 6 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $201.85 | 11 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $179.38 | 7 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $116.50 | 6 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $109.06 | 4 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $108.59 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $74.80 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $69.52 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $57.85 | 3 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $49.67 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $48.85 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $47.26 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $46.51 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.18 | 3 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $42.30 | 3 | 2025 |
Source payment records
|
|||||
| OPTISURE Normalized: optisure |
Device | Abbott Laboratories | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| TENDRIL Normalized: tendril |
Device | Abbott Laboratories | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $27.79 | 2 | 2025 |
Source payment records
|
|||||
| ALLURE QUADRA Normalized: allure quadra |
Device | Abbott Laboratories | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| ISOFLEX Normalized: isoflex |
Device | Abbott Laboratories | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| TYRX Normalized: tyrx |
Device | Medtronic, Inc. | $13.06 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $9.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 53 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 207 | 53 |
| Amiodarone Hcl | Amiodarone Hcl | 200 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 148 | 47 |
| Furosemide | Furosemide | 131 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 116 | 35 |
| Carvedilol | Carvedilol | 87 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 30 |
| Metolazone | Metolazone | 78 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 18 |
| Flecainide Acetate | Flecainide Acetate | 50 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 20 |
| Losartan Potassium | Losartan Potassium | 47 | 21 |
| Warfarin Sodium | Warfarin Sodium | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Xarelto | Rivaroxaban | 40 | 12 |
| Lisinopril | Lisinopril | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,440.33 · 115 records | Medtronic, Inc. | ALLURE QUADRA, AMVIA EDGE, ASSURITY, AVEIR, AZURE XT DR MRI SURESCAN, Assure WCD, Barostim Neo System, CAMZYOS, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, FFRct, FUROSCIX, GALLANT, Hillrom - Carnation Ambulatory Monitor, ISOFLEX, JARDIANCE, JOT DX, LEQVIO, LINQ II, MCOT, MERLIN@HOME, ONPATTRO, OPTISURE, Optimizer, Repatha, SAPIEN 3 Ultra RESILIA, TENDRIL, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TYRX, VITALPATCH RTM | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error